Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments

OBJECTIVES: To evaluate the efficacy and safety of ustekinumab (UST) in a multicentre, randomised, double-blind, placebo-controlled trial in adult Japanese patients with active polymyositis (PM) and dermatomyositis (DM). METHODS: Fifty-one Japanese adults diagnosed with active PM/DM who did not resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahata, Kimito, Ishii, Tomonori, Gono, Takahisa, Tsuchiya, Yumi, Ohashi, Hiroki, Yoshizawa, Katsunori, Zheng, Richuan, Ayabe, Maori, Nishikawa, Kazuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Myositis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476119/
https://www.ncbi.nlm.nih.gov/pubmed/37652554
http://dx.doi.org/10.1136/rmdopen-2023-003268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476119/
https://www.ncbi.nlm.nih.gov/pubmed/37652554
http://dx.doi.org/10.1136/rmdopen-2023-003268

Ejemplares similares